Lilly Hopes To Differentiate Omvoh In Crohn’s With Histologic Data

The IL-23 antagonist Omvoh is under FDA/EMA review for Crohn’s disease; Lilly reported new Phase III data showing the drug is better than Stelara on multiple endpoints of histologic response.